Travere CFO sells 50K shares after option exercise

Travere Therapeutics’ CFO exercised 20,000 options and sold 50,508 TVTX shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) reports that its chief financial officer, Christopher R. Cline, exercised employee stock options for 20,000 shares of common stock at an exercise price of $17.44 per share on September 15, 2026, and the corresponding option position was reduced to zero. On the same date, he sold an aggregate of 50,508 shares of common stock in multiple open-market transactions at weighted average prices between approximately $62.00 and $65.31 per share. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Cline Christopher R.

Role CHIEF FINANCIAL OFFICER

Sold 50,508 shs ($3.15M)

Approx. gross sale proceeds $3.15M

Approx. exercise cost $349K

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) F5	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$17.44	$349K
Sale	Common Stock F1, F2	27,473	$61.9969	$1.70M
Sale	Common Stock F1, F3	20,735	$62.6079	$1.30M
Sale	Common Stock F1, F4	1,900	$63.6865	$121K
Sale	Common Stock F1	400	$65.31	$26K

Holdings After Transaction: Employee stock option (right to buy) — 0 contracts (Direct); Common Stock — 87,508 shares (Direct)

Footnotes (5)

1. F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
2. F2. The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
3. F3. The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
5. F5. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 20,000 shares Option exercise price: $17.44 per share Total shares sold: 50,508 shares +5 more

8 metrics

Options exercised 20,000 shares Employee stock options for Travere Therapeutics common stock exercised on September 15, 2026

Option exercise price $17.44 per share Exercise price of employee stock options covering 20,000 shares

Total shares sold 50,508 shares Aggregate common shares sold by the CFO on September 15, 2026

Sale tranche 1 27,473 shares at $61.9969 Weighted average sale price with trades between $61.38 and $62.37

Sale tranche 2 20,735 shares at $62.6079 Weighted average sale price with trades between $62.38 and $63.30

Sale tranche 3 1,900 shares at $63.6865 Weighted average sale price with trades between $63.59 and $63.86

Sale tranche 4 400 shares at $65.31 Open-market sale price per share

Remaining options from this grant 0 options Total options following exercise of 20,000 options expiring May 17, 2027

Key Terms

Rule 10b5-1(c), weighted average sale price, Employee stock option, fully vested and exercisable

4 terms

Rule 10b5-1(c) regulatory

"adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $61.9969"

Employee stock option financial

"Employee stock option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Travere Therapeutics (TVTX) report for its CFO?

Travere Therapeutics reported that CFO Christopher R. Cline exercised 20,000 stock options at $17.44 per share and sold an aggregate of 50,508 common shares in multiple open-market transactions on September 15, 2026.

How many Travere Therapeutics (TVTX) options did the CFO exercise and at what price?

The CFO exercised 20,000 employee stock options of Travere Therapeutics common stock at an exercise price of $17.44 per share on September 15, 2026, and the related option position reported on this form was reduced to zero.

How many Travere Therapeutics (TVTX) shares did the CFO sell and at what prices?

On September 15, 2026, the CFO sold 50,508 TVTX shares in several trades, including 27,473 shares at a weighted average of $61.9969, 20,735 shares at $62.6079, 1,900 shares at $63.6865, and 400 shares at $65.31 per share.

Were the Travere Therapeutics (TVTX) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a written trading plan adopted on June 16, 2026, that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

Did the Travere Therapeutics (TVTX) CFO’s exercised option remain outstanding after the transaction?

No. The reported employee stock option for 20,000 shares, which was fully vested and exercisable, shows 0 options remaining following the September 15, 2026 exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:31 PM Accepted by SEC EDGAR 09/17/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		20,000	A	$17.44	138,016	D
Common Stock	09/15/2026		S(1)		27,473	D	$61.9969(2)	110,543	D
Common Stock	09/15/2026		S(1)		20,735	D	$62.6079(3)	89,808	D
Common Stock	09/15/2026		S(1)		1,900	D	$63.6865(4)	87,908	D
Common Stock	09/15/2026		S(1)		400	D	$65.31	87,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$17.44	09/15/2026		M			20,000	(5)	05/17/2027	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

2. The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)